Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company VBI Vaccines Inc.
DescriptionBivalent vaccine against human cytomegalovirus (CMV) glycoprotein B and phosphoprotein 65 (pp65; UL83) with a GM-CSF
Molecular Target Human cytomegalovirus (CMV) glycoprotein B ; Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat cytomegalovirus (CMV)-positive glioblastoma multiforme (GBM)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today